These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29020426)

  • 21. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphologic characterization of dome-shaped macula in myopic eyes with serous macular detachment.
    Caillaux V; Gaucher D; Gualino V; Massin P; Tadayoni R; Gaudric A
    Am J Ophthalmol; 2013 Nov; 156(5):958-967.e1. PubMed ID: 23972305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
    Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
    Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
    Chan CK; Jain A; Sadda S; Varshney N
    Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial utilization of aflibercept in exudative age-related macular degeneration.
    Cho H; Weber ML; Shah CP; Heier JS
    Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION.
    Matsumoto H; Sato T; Morimoto M; Mukai R; Takahashi M; Hiroe T; Ehara K; Takayama M; Mimura K; Kishi S
    Retina; 2016 Dec; 36(12):2282-2289. PubMed ID: 27336229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS.
    He L; Silva RA; Moshfeghi DM; Blumenkranz MS; Leng T
    Retina; 2016 Mar; 36(3):492-8. PubMed ID: 26398694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis.
    Choi CS; Zhang L; Abràmoff MD; Sonka M; Shifera AS; Kay CN
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):245-51. PubMed ID: 26985798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy.
    Kovach JL; Hess H; Rosenfeld PJ
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):593-5. PubMed ID: 27327292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT.
    Chhablani J; Dedhia CJ; Peguda HK; Stewart M
    Retina; 2017 Oct; 37(10):1859-1865. PubMed ID: 28060148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.